Skip to content

The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease

The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00915616
Enrollment
Unknown
Registered
2009-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2009-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease

Brief summary

Gastro-Esophageal Reflux Disease was defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is widely used anti-ulcer drug and has been demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in human either alone and in combination with omeprazole therapy.

Interventions

DRUGMelatonin

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
42 Years to 56 Years
Healthy volunteers
Yes

Inclusion criteria

* patient with GERD ranged from 42 to 56 years

Exclusion criteria

* patients with cardiac disease * patients with renal affection * patients with liver diseases (due to drug induced, autoimmune disease and viral hepatitis) * patients on the drugs known to affect the GIT motility (phenothiazines, anticholinergics, nitrates or calcium channel blockers) were excluded during the time of conduction of the study or the preceding two weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026